Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Kobe Univ. Aims to Become APEC “Center of Excellence”; Could Promote Stronger Japanese Role in Regulatory Harmonization
Kobe University aims to obtain certification as an APEC Training Center of Excellence for Regulatory Science (CoE), an initiative through which APEC certifies institutions in the region to train personnel at regulatory authorities. The certification is an initiative of APEC’s…
To read the full story
Related Article
- Kobe Univ. Received Pilot Certification as APEC Training Center of Excellence
September 20, 2019
- New “Center of Excellence” to Be Set Up in US to Train Regulators from APEC Region, Promote Multiregional Clinical Trials
September 5, 2018
- PMDA Certified as APEC’s Training Center of Excellence for Regulatory Science
March 6, 2017
ACADEMIA
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
- CAR-T Reimbursement Insufficient, Kyoto University Hospital Chief Warns
March 11, 2026
- Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
March 3, 2026
- 63% of OB-GYN Clinics Adopt RSV Maternal Vaccine 1 Year after Launch
February 25, 2026
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…